65 completed, 12 recruiting, 11 unknown, 10 terminated. 111 Phase 2, 18 Phase 1, 11 Phase 3.
Follow salicylhydroxamic acid: new trials by email Literature Review of salicylhydroxamic acid trials Research Report on salicylhydroxamic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Moxifloxacin, Placebo - Endophthalmitis | Phase 2 / Phase 3 | Not yet recruiting | Jason Ahee, M.D. | 60000 | 2027-06-01 | 2026-09-15 |
| Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial Faricimab, Sham - Central Serous Chorioretinopathy (CSC) | Phase 2 | Not yet recruiting | Singapore National Eye Centre | 50 | 2026-12-01 | 2026-07-02 |
| Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury Focused extracorporeal shockwave therapy, Botulinum toxin, Sham - Spinal Cord Injury, Spasticity | Phase 2 | Recruiting | Kessler Foundation | 30 | 2026-09-21 | 2026-10-28 |
| A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF - Diabetic Macular Edema (DME) | Phase 2 | Recruiting | BioAge Labs, Inc. | 180 | 2026-08-21 | 2026-10-27 |
| RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham - Overactive Bladder (OAB) | Phase 2 | Recruiting | Vensica Therapeutics Ltd. | 210 | 2026-08-14 | 2026-10-16 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection - Geographic Atrophy Due to Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Theratocular Biotek Co. | 31 | 2026-06-02 | 2026-06-25 |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Surabgene Lomparvovec, Sham, Topical Steroid - Diabetic Retinopathy | Phase 2 / Phase 3 | Recruiting | AbbVie | 576 | 2026-06-01 | 2026-10-29 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) ST-503, Sham (No Treatment) - Chronic Neuropathic Pain | Phase 1 / Phase 2 | Recruiting | Sangamo Therapeutics | 27 | 2025-12-04 | 2026-06-01 |
| Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham - Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD) | Phase 2 | Recruiting | ONL Therapeutics | 324 | 2025-10-28 | 2026-09-10 |
| Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. XC001, Sham (No Treatment) - Refractory Angina, Coronary Artery Disease | Phase 2 | Recruiting | XyloCor Therapeutics, Inc. | 106 | 2025-07-08 | 2026-09-11 |
| Synergistic Effect of Non-invasive Brain and Spinal Cord Stimulation tDCS, tSCS, Sham - Stroke, Spinal Cord Injury | Phase 2 | Recruiting | Centre National de la Recherche Scientifique, France | 45 | 2024-12-11 | 2026-01-12 |
| Bupivacaine and Epinephrine Injection Study Sensorcaine with Epinephrine, Sham injection - Sinus Disease, Anesthesia | Phase 2 / Phase 3 | Recruiting | Amin Javer | 80 | 2024-11-15 | 2025-05-15 |
| ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs VIA Disc NP, Sham Injection - Degenerative Disc Disease, Disc Degeneration | Phase 2 | Active not recruiting | VIVEX Biologics, Inc. | 121 | 2024-10-04 | 2026-10-05 |
| Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial Methotrexate Injection, Methotrexate Infusion, Sham Injection - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 2 | Recruiting | Cincinnati Eye Institute, Southwest Ohio | 860 | 2024-03-01 | 2026-10-29 |
| The Herbal Acupoint Patch for Dialysis Patient With Fistula-related Pain Artemisias-ginger patch (AGP), Sham (No Treatment) - End Stage Chronic Renal Failure, Myofacial Pain | Phase 1 / Phase 2 | Completed | Chang Gung Memorial Hospital | 21 | 2024-02-15 | 2026-02-02 |
| Effect of Osteopathy Medicine on Post-surgical Management of Lumbosacral Arthrodesis manual therapy, Sham - Arthrodesis, Post-operative Care | Phase 2 | Completed | Centre Européen d'Enseignement Supérieur de l'Ostéopathie de Lyon | 35 | 2023-03-01 | 2024-11-01 |
| Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment THC ~2.5%, THC ~5%, THC ~10% - Migraine, Cannabis | Phase 2 | Suspended | University of California, San Diego | 20 | 2023-02-15 | 2026-03-16 |
Showing 20 of 111. Sign in to see all of them.
Macular Degeneration (16) · Geographic Atrophy (10) · Diabetic Retinopathy (7) · Retinal Diseases (7) · Diabetes Mellitus (5) · Choroidal Neovascularization (4) · Macular Edema (4) · Retinitis Pigmentosa (4) · Eye Diseases (3) · Intervertebral Disc Degeneration (3) · Spinal Cord Injuries (3) · Stroke (3) · Blindness (2) · Brain Injuries, Traumatic (2) · Central Serous Chorioretinopathy (2)
Allergan (12) · Alcon Research (3) · ThromboGenics (3) · University of California, San Diego (3) · Evon Medics LLC (2) · Fondazione Policlinico Universitario Campus Bio-Medico (2) · Genentech, Inc. (2) · Imperial College London (2) · National Center for Complementary and Integrative Health (NCCIH) (2) · Neurotech Pharmaceuticals (2) · Opthea Limited (2) · Santen Pharmaceutical Co., Ltd. (2) · University of Chicago (2) · University of Sao Paulo (2) · AbbVie (1)
United States (73) · Germany (15) · United Kingdom (15) · France (14) · Italy (14) · Israel (12) · Australia (11) · Canada (8) · South Korea (8) · Spain (7) · Brazil (6) · Czechia (6) · Portugal (6) · Belgium (5) · Hungary (5)
Nathaniel M Schuster, MD (2) · Peter Nagele, MD, MSc (2) · Adam Rosenberg, MD (1) · Aline Rollet, Ostéopathe DO, MsC Cand. (1) · Angelino J Cariello, MD (1) · Benoit H Mulsant, MD (1) · Bradley A Edwards, PhD (1) · Carl LeBel, PhD (1) · Claire Winterson (1)
PMID 37314061, PMID 32134802, PMID 20351373, PMID 20980427, PMID 21220619, PMID 21441148, PMID 21672495, PMID 23049090, PMID 23411886, PMID 23761087, PMID 25315664, PMID 25532706, PMID 26438108, PMID 26908704, PMID 27858723, PMID 27893095, PMID 28185625, PMID 28220291, PMID 28364678, PMID 28454823, PMID 29127949, PMID 29530781, PMID 30194931, PMID 30633959, PMID 31072380, PMID 31175209, PMID 31388454, PMID 31747864, PMID 32250312, PMID 32311925, PMID 32769645, PMID 32882310, PMID 33343483, PMID 33383315, PMID 33588087, PMID 33734306, PMID 34101138, PMID 34185587, PMID 35005990, PMID 35951718, PMID 36463457, PMID 36754174, PMID 38489195, PMID 39495154, PMID 39538001, PMID 39688178, PMID 40235521, PMID 40261111, PMID 40522203, PMID 41469488
2015 (2), 2017 (2), 2019 (2), 1UM1HL113203-01A1 (1), 2014 (1), 2018 (1), R01HD081274 (1), R01HL128658 (1), R21HD123083 (1), R44AG061981 (1), R44DA049616 (1), R44HL117572 (1), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1)